Comparison of Chloral Hydrate Solution, Hydroxyzine Syrup, and Lidocaine/Prilocaine Cream as Premedication for Lumbar Puncture in Children: A Double-Blind Study.

Chloral Hydrate Hydroxyzine Lidocaine/Prilocaine Cream Lumbar Puncture Premedication

Journal

Iranian journal of child neurology
ISSN: 1735-4668
Titre abrégé: Iran J Child Neurol
Pays: Iran
ID NLM: 101463836

Informations de publication

Date de publication:
2022
Historique:
received: 11 01 2022
accepted: 07 02 2021
entrez: 7 10 2022
pubmed: 8 10 2022
medline: 8 10 2022
Statut: ppublish

Résumé

This study aimed to compare the clinical effectiveness of oral hydroxyzine and chloral hydrate to topical lidocaine/prilocaine 2.5% cream as premedication in pediatric leukemia patients. This double-blind clinical trial study was conducted on 70 leukemic and nonleukemic patients aged 3-11 years. The patients were divided into four groups. In group A, chloral hydrate solution was given to 18 patients. In group B, hydroxyzine syrup was used for 18 patients. In group C, chloral hydrate solution and lidocaine/prilocaine cream were used for 17 patients. In group D, hydroxyzine syrup and lidocaine/prilocaine cream were used for 17 patients. These groups were assessed and judged based on the visual analog scale (VAS). The side effects of the drugs were also recorded. In this study, 54.3% (n=38) and 45.7% (n=32) of the cases were female and male, respectively. Furthermore, 77%, 7.2%, and 15.8% of the cases were reported with acute lymphocytic leukemia, acute myeloid leukemia, and infectious disease, respectively. The VAS results showed no difference in these four groups. Nontraumatic lumbar puncture (LP) (red blood cell<50) was observed in 97.1% of the cases. Although premedications for LP with hydroxyzine syrup and chloral hydrate solution were not statistically effective in pain relief, they increased patient and parent satisfaction. Moreover, adding lidocaine/prilocaine cream does not improve the effectiveness of the drugs.

Identifiants

pubmed: 36204436
doi: 10.22037/ijcn.v16i3.28605
pmc: PMC9531204
doi:

Types de publication

Journal Article

Langues

eng

Pagination

29-34

Informations de copyright

© 2022 The Authors.

Déclaration de conflit d'intérêts

None

Références

BMC Cancer. 2009 Jan 15;9:21
pubmed: 19146666
Iran J Ped Hematol Oncol. 2015;5(3):131-7
pubmed: 26705451
Ann Emerg Med. 2003 Dec;42(6):783-91
pubmed: 14634603
Blood. 2006 Aug 15;108(4):1165-73
pubmed: 16609069
Pediatr Blood Cancer. 2015 Jan;62(1):85-90
pubmed: 25264024
Cancer. 2010 May 15;116(10):2290-300
pubmed: 20209620
Dan Med J. 2013 Jun;60(6):A4627
pubmed: 23743110
J Clin Med Res. 2011 Jul 26;3(4):164-7
pubmed: 22121399
Pediatr Dent. 2019 Jul 15;41(4):259-260
pubmed: 31439084
Acta Med Croatica. 2013 Dec;67(5):401-5
pubmed: 24979880
Iran J Child Neurol. 2013 Spring;7(2):11-6
pubmed: 24665291

Auteurs

Hossein Esfahani (H)

Pediatric Hematologist/Oncologist, Hamadan University of Medical Sciences, Hamadan, Iran.

Iraj Sedighi (I)

Pediatric Infectious Disease, Hamadan University of Medical Sciences, Hamadan, Iran.

Maryam Sahraei (M)

Pediatric Resident, Hamadan University of Medical Sciences, Hamadan, Iran.

Mohammad Ali Seif Rabie (MA)

Public Health, Hamadan University of Medical Sciences, Hamadan, Iran.

Firozeh Hosseini (F)

Pediatric Neurologist, Hamadan University of Medical Sciences, Hamadan, Iran.

Classifications MeSH